Association between dipeptidyl peptidase-4 inhibitor and acute kidney injury
Not Applicable
Not yet recruiting
- Conditions
- Adult with diabetes mellitus
- Registration Number
- JPRN-UMIN000051147
- Lead Sponsor
- Kaetsu Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Children, transplantation, gestational diabetes, use of DPP4 inhibitors for non-diabetics mellitus, and no outcome assessment for acute kidney injury.
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Acute kidney injury
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link DPP-4 inhibitors to acute kidney injury in diabetic patients?
How do DPP-4 inhibitors compare to other antidiabetic drugs in terms of renal safety profiles?
Are there specific biomarkers that identify diabetic patients at higher risk of DPP-4 inhibitor-induced acute kidney injury?
What are the potential adverse events associated with DPP-4 inhibitors in diabetes management and how can they be managed?
What is the current evidence on the association between DPP-4 inhibitors and acute kidney injury from meta-analyses and observational studies?